September 14, 2016 – (RepliCel) – “RepliCel Life Sciences Inc. (“RepliCel” or the “Company”), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today it intends to undertake a non-brokered private placement financing, on a commercially reasonable basis, of up to 8,000,000 units (each, a “Unit“) at a price of $0.52 per Unit for gross proceeds of up to $4,160,000 (the “Offering“). Each Unit will consist of one common share of the Company (each, a “Share“) and one share purchase warrant (each, a “Warrant“), with each Warrant entitling the holder to purchase one additional Share for a period of two years from the closing of the Offering at a price of $1.10 per Share.” Read Full Press Release